Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-10-14
DOI
10.1038/s41467-017-01018-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
- (2016) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
- (2015) Sachet A Shukla et al. NATURE BIOTECHNOLOGY
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Systematic pan-cancer analysis of tumour purity
- (2015) Dvir Aran et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
- (2015) W. Joost Lesterhuis et al. Scientific Reports
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Prediction of Response to Anticancer Immunotherapy Using Gene Signatures
- (2013) Ena Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
- (2013) Wim H.J. Kruit et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
- (2013) Fernando Ulloa-Montoya et al. JOURNAL OF CLINICAL ONCOLOGY
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Mucin-based Targeted Pancreatic Cancer Therapy
- (2012) Maria P. Torres et al. CURRENT PHARMACEUTICAL DESIGN
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
- (2012) Y. Yuan et al. Science Translational Medicine
- MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge
- (2012) David Roulois et al. Biomed Research International
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma
- (2011) G. R. Weiss et al. CLINICAL CANCER RESEARCH
- Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer
- (2011) Sang Cheul Oh et al. GUT
- gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
- (2011) Douglas J. Schwartzentruber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- (2011) Craig H Mermel et al. GENOME BIOLOGY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started